Liver fibrosis in non-alcoholic fatty liver disease
Conditions
Interventions
1:Oral administration of silybin capsules silymarin capsules vitamin E soft capsules and other Western medicines for treatment
2:Under the precise diagnosis and treatment of Professor Zhao and his team in traditional Chinese medicine the clinical syndrome differentiation is divided into "deficiency syndrome" and "excess syndr
Sponsors
The First Affiliated Hospital of Henan University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
16 Years to 70 Years
Inclusion criteria
Inclusion criteria: (1) Age 16 to 70 gender not limited; (2) Meet the diagnostic criteria of both Chinese and Western medicine; (3) There are at least two or more non-invasive test results of liver function blood routine and liver fiber and the LSM of the first non-invasive test of liver fiber is =7.3kPa and the Cap is =238dB/m; (4) The treatment duration is =3 months
Exclusion criteria
Exclusion criteria: It will be excluded if any of the following conditions is met. Exclude other liver diseases such as hepatitis C hepatitis B and autoimmune hepatitis. (2) Fatty liver caused by long-term use of glucocorticoids chlorpromazine insulin etc. (3) Patients with type 1 diabetes; (4) Patients with various malignant tumors or those with a history of malignant tumors in the past; (5) Those in the decompensated stage of liver cirrhosis and liver failure.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| FibroScan non-invasively detects liver stiffness values;Liver Fibrosis Score (GPR);Liver fibrosis score(NFS); | — |
Secondary
| Measure | Time frame |
|---|---|
| Body mass index;Non-invasive detection of liver fiber controlled attenuation parameters;liver function;TCM Syndrome Score; | — |
Countries
China
Contacts
Public ContactLiu Xiaoyan
The First Affiliated Hospital of Henan University of Chinese Medicine
Outcome results
None listed